Original Article
Copyright ©2014 Baishideng Publishing Group Inc.
World J Hepatol. Aug 27, 2014; 6(8): 613-620
Published online Aug 27, 2014. doi: 10.4254/wjh.v6.i8.613
Table 1 Clinical and demographic characteristics of non-alcoholic fatty liver disease patients and controls
VariableNAFLD (n = 20)Control (n = 20)P
Age (yr)42.75 ± 8.1744.50 ± 9.310.761
Sex (male/female)9 (45.0)/11(55.0)9 (45.0)/11 (55.0)0.761
BMI (kg/m2)31.86 ± 4.7627.26 ± 3.070.006
Waist circumference (cm)103.25 ± 13.6590.75 ± 11.020.014
Systolic blood pressure (mmHg)120.25 ± 8.66120.25 ± 7.690.999
Diastolic blood pressure (mmHg)76.50 ± 6.0977.50 ± 8.960.761
Fasting glucose (mg/dL)97.85 ± 13.8886.80 ± 11.920.034
Triglycerides (mg/dL)151.10 ± 65.06167.70 ± 51.460.645
HDL-C (mg/dL)43.00 (36.50-48.50)45.00 (38.45-49.95)0.761
LDL-C (mg/dL)125.50 (100.00-139.00)108.00 (89.25-121.25)0.511
Insulin (mIU/mL)14.81 (11.88-22.75)11.76 (8.61-15.70)0.229
HOMA-IR4.05 (2.71-5.51)2.21 (1.77-3.12)0.034
Total biluribin (mg/dL)0.65 (0.50-0.80)0.60 (0.55-0.80)0.761
Direct biluribin (mg/dL)0.20 (0.12-0.25)0.20 (0.10-0.20)0.761
AST (IU/L)45.00 (34.50-59.00)21.00 (18.00-27.00)< 0.001
ALT (IU/L)68.50 (52.50-85.50)18.50 (14.00-29.00)< 0.001
AP (IU/L)76.00 (55.50-96.00)69.00 (57.00-78.50)0.761
GGT (IU/L)48.00 (33.00-73.00)20.00 (14.50-33.00)< 0.001
Creatinine (mg/dL)0.87 ± 0.150.80 ± 0.180.401
WBC (μL)6709.50 ± 1709.476618.00 ± 1425.370.892
Trombocyte (103/μL)252.10 ± 64.85275.90 ± 69.820.511
Hct43.37 ± 3.5344.25 ± 4.190.761
Table 2 Log2 (Fold change) ratios of differentially expressed miRNAs which were statistically significant by t test (P < 0.05) and further confirmed by SAM test (q < 5%)
miRNAslog2 (Fold change)
q value (%)
MeanSEM
Over-expressed
----
Under-expressed
miR-197-1.610.540
miR-146b-1.520.550
miR-181d-2.490.500
miR-99a-1.920.530
Table 3 Point-biserial correlation coefficients between NAS-scale parameters and miRNAs in non-alcoholic fatty liver disease patients
miR-197miR-146bmiR-10bmiR-181dmiR-34amiR-122miR-99amiR-29a
Steatosis0.2290.1910.1790.1790.2450.0670.3110.256
Inflammation-0.4571-0.396-0.4921-0.402-0.302-0.23-0.431-0.315
Ballooning0.1540.1140.1750.2540.165-0.037-0.0290.096
Fibrosis-0.112-0.171-0.213-0.0980.033-0.137-0.197-0.103
NAS0.0510.0150.0350.0690.124-0.0270.0740.041
Table 4 Correlation analysis between laboratory parameters and miRNAs in non-alcoholic fatty liver disease patients
miR-197miR-146bmiR-10bmiR-181dmiR-34amiR-122miR-99amiR-29a
AST-0.257-0.331-0.225-0.252-0.084-0.225-0.138-0.322
ALT-0.131-0.147-0.080-0.2150.1220.1030.077-0.143
GGT-0.327-0.225-0.303-0.4641-0.29-0.231-0.4791-0.221
Triglyceride0.008-0.0390.009-0.035-0.0750.087-0.239-0.058
HDL-C0.0270.051-0.0310.0420.0520.1110.160.034
LDL-C0.0780.0420.0670.0150.1390.1020.2130.155
HOMA-IR-0.0550.1170.011-0.0150.1950.2050.2210.177
Table 5 Statistical diagnostic measures for miR-197, miR-146b, miR-181d and miR-99a in identifying non-alcoholic fatty liver disease
miRNACut-off valueSEN (95%CI)SPE (95%CI)PPV (95%CI)NPV (95%CI)
miR-197 ≤ -1.014460.0 (36.1-80.9)95.0 (75.1-99.9)92.3 (64.0-99.8)70.4 (49.8-86.2)
miR-146b ≤ -0.768955.0 (31.6-76.9)100.0 (83.0-100.0)100.0 (71.3-100.0)69.0 (49.2-84.7)
miR-181d ≤ -0.286170.0 (45.7-88.0)85.0 (62.1-96.6)82.4 (56.6-96.0)73.9 (51.6-89.7)
miR-99a ≤ -0.156265.0 (40.8-84.5)95.0 (75.1-99.2)92.9 (66.1-98.8)73.1 (52.2-88.4)